Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1846 Target Snapshot

Ryanodine receptor 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
37Compounds
11Assays
0Approved Drugs
12.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Ryanodine receptor 1 shows approved-linked disease relevance led by cerebral palsy. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P21817. Start with cerebral palsy, then reuse UniProt P21817 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cerebral palsy, then reuse UniProt P21817 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
cerebral palsy

Ryanodine receptor 1 shows approved-linked disease relevance led by cerebral palsy. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cerebral palsy because it currently carries approved-linked support. Linked drugs include DANTROLENE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ryanodine receptor 1 as ChEMBL target CHEMBL1846, mapped to UniProt P21817. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ryanodine receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1846
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P21817
Ryanodine receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Ryanodine receptor 1 is the right protein anchor across sources, using UniProt P21817 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cerebral palsy is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameRyanodine receptor 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP21817
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRyanodine receptor 1
UniProt AccessionP21817
Component TypeProtein
Sequence Length5038 aa

Ryanodine receptor 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Ryanodine receptor 1, mapped to UniProt P21817. Sequence length is 5038 aa.

Mapped IDP21817
Review nameRyanodine receptor 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Ryanodine receptor 1 shows approved-linked disease relevance led by cerebral palsy. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cerebral palsy
1 linked drug · 1 direct · 1 efficacy
Linked drugDANTROLENE SODIUM
Approved-linked Approved
Fever
1 linked drug · 1 direct · 1 efficacy
Linked drugDANTROLENE SODIUM
Approved-linked Approved
Malignant hyperthermia
1 linked drug · 1 direct · 1 efficacy
Linked drugDANTROLENE SODIUM
Approved-linked Approved
multiple sclerosis
1 linked drug · 1 direct · 1 efficacy
Linked drugDANTROLENE SODIUM
Approved-linked Approved
Spasticity
1 linked drug · 1 direct · 1 efficacy
Linked drugDANTROLENE SODIUM
Approved-linked Approved
Spinal cord injury
1 linked drug · 1 direct · 1 efficacy
Linked drugDANTROLENE SODIUM
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cerebral palsy because it currently carries approved-linked support. Linked drugs include DANTROLENE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecerebral palsy
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC503.0
KI1.0
EC508.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL308183 8.74 Ki 1.8 Preclinical
CHEMBL308183 8.48 IC50 3.3 Preclinical
CHEMBL439151 5.66 EC50 2200.0 Preclinical
CHEMBL505907 5.58 EC50 2600.0 Preclinical
CHEMBL504851 5.24 EC50 5800.0 Preclinical
CHEMBL213853 5.22 IC50 6000.0 Preclinical
CHEMBL360190 5.2 EC50 6300.0 Preclinical
CHEMBL386905 4.96 EC50 11000.0 Preclinical
CHEMBL455487 4.83 EC50 14700.0 Preclinical
Distribution

pChEMBL Value Distribution

3
5.0
2
5.5
0
6.0
0
6.5
0
7.0
0
7.5
2
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

11
Total Assays
10
Tested Compounds
2
Assay Types
Binding — 8 assays, 10 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 5 8 5.6
assay format 1 1 8.5
cell membrane format 1 1 8.7
cell-based format 1 0 —
Functional — 3 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
tissue-based format 3 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine